A cross-sectional study of 76 adults with Crohn’s disease at a Baghdad hospital found that higher ustekinumab trough ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Both drugs showed safety and efficacy at 3 and 6 months. Ustekinumab achieved significantly longer treatment ...

For patients with moderate-to-severe Crohn's disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for endoscopic remission at week 48, according to a ...

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...

In a recent study published in The New England Journal of Medicine, researchers discuss the results of a randomized clinical trial (RCT) comparing the therapeutic efficacy of risakizumab and ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of ustekinumab, having considered evidence on the nature of psoriatic arthritis and the value placed on the ...

The US Food and Drug Administration (FDA) has approved ustekinumab-auub (Wezlana) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. This is the first ...

Remission rates were found to be high after ustekinumab induction among patients with Crohn disease (CD) who had a previously failed anti-tumor necrosis factor (TNF) therapy attempt, according to ...

Please provide your email address to receive an email when new articles are posted on . Long-term ustekinumab effectively and safely treated most patients in a “difficult-to-treat” Crohn’s disease ...

A US government report showed how a Medicare policy change made the drug ustekinumab (Stelara) for autoimmune diseases much more expensive, a finding that experts say illustrates the need for reforms ...